Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (Symbol: CDXS) is a pioneering leader in protein engineering, pushing the boundaries of biotechnology through its innovative approaches. Established in 2002, Codexis specializes in the rapid development and production of highly optimized proteins using its proprietary CodeEvolver® technology platform. This platform leverages the power of artificial intelligence and advanced high-throughput screening systems to efficiently introduce function-driven mutations, creating proteins meticulously tailored to meet specific performance requirements.
Codexis offers a broad spectrum of enzyme optimization services and biocatalyst products. These include biocatalysts and enzymes, which play crucial roles in various industries, including pharmaceuticals, food, and biofuels. The company's enzyme solutions are designed to improve the efficiency, cost-effectiveness, and environmental sustainability of production processes.
A significant portion of Codexis’ revenue is derived from product sales, while licensing its technology platform to pharmaceutical companies also contributes to its financial health. These partnerships enable pharmaceutical giants to harness Codexis’ technology in-house, facilitating the engineering of custom enzymes for their specific needs.
Codexis has a global revenue footprint, with contributions from the United States, Ireland, Switzerland, China, and other international markets. The company's innovative efforts have led to several strategic partnerships and collaborations, further cementing its position in the biotechnology sector.
Recent achievements include a strategic collaboration geared towards enhancing RNA therapeutic development, aimed at providing GMP-grade Codexis enzymes. Another notable development is the collaboration with TnX transposase, focusing on enhancing genomic applications.
Codexis continues to advance in the field of biotherapeutics, retaining economic interest while minimizing development and commercialization costs. The company remains committed to optimizing yield, purity, and quality in its offerings, ensuring that customers receive superior siRNA materials for preclinical testing.
For more information, Codexis frequently participates in industry conferences, presenting breakthrough research and advancements. Stay updated with the latest developments and announcements by following Codexis on various platforms.
Codexis (Nasdaq: CDXS) announced a public offering of 4,285,715 shares at $17.50 each, aiming to raise approximately $70.2 million after expenses. The offering is expected to close around December 7, 2020, pending customary conditions. Proceeds will support R&D and infrastructure to enhance performance enzymes and biotherapeutics, as well as fund potential acquisitions or investments. Jefferies LLC, Cowen and Company, LLC, and Stifel are managing the offering, with an additional 642,857 shares available for underwriters within 30 days.
Codexis (Nasdaq: CDXS) has launched an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The net proceeds will fund R&D, enhance infrastructure, and support the development of performance enzymes and biotherapeutics. Codexis may also invest in complementary businesses. Notably, Jefferies LLC, Cowen and Company, and Stifel are managing the offering. Market conditions may impact the completion and terms of this offering.
Codexis (NASDAQ: CDXS) and Casdin Capital have launched the SynBio Innovation Accelerator, aimed at funding early-stage companies in synthetic biology. This initiative will see Casdin planning to invest upwards of $50 million in the sector. The first investment is a $1.75 million stake in Arzeda, a computational protein design firm, where both companies will collaborate to enhance enzyme development using machine learning. John Nicols, CEO of Codexis, emphasized the transformative potential of synthetic biology, while Eli Casdin highlighted the accelerator's role in stimulating innovation.
Codexis, a leader in protein engineering, announced its participation in three virtual investment conferences. The events include the Stifel Healthcare Conference on November 16, 2020, at 3:20 p.m. ET, the 11th Annual Craig-Hallum Alpha Select Conference on November 17, 2020, and the Stephens Annual Investment Conference on November 18, 2020, at 1:00 p.m. ET. Presentations will be webcasted and available for replay on the company's investor website. Codexis utilizes its proprietary technology for developing proteins for pharmaceuticals and industrial applications.
Codexis, Inc. (Nasdaq: CDXS) reported total revenues of $18.4 million for Q3 2020, a drop from $21.9 million in Q3 2019. Product revenue was $8.4 million, down from $10.4 million year-over-year, largely due to demand timing. R&D revenue decreased to $10.0 million from $11.6 million, impacted by fewer milestone payments. Despite a net loss of $6.1 million, management expects 2020 revenue to exceed pre-COVID guidance, with robust growth across its segments, including Novel Biotherapeutics.
Codexis, a leader in protein engineering, is set to announce its third quarter 2020 financial results on November 5, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide company updates. Investors are encouraged to pre-register for the call to streamline access. The announcement underlines Codexis' focus on transparency and engagement with its investment community.
Codexis, a leading protein engineering company, announced its participation in two upcoming virtual investment conferences. The first event is the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 a.m. ET. The second is the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. A live webcast and replay will be available on their Investors website.
Codexis, Inc. (NASDAQ: CDXS) will report its second quarter 2020 financial results on August 6, 2020, after the market closes. The management team will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company. Participants can pre-register for the call to receive a passcode for immediate access. A live webcast will also be available on the Codexis investor relations website, with an archive accessible for 90 days. For those unable to attend live, a replay will be available for 48 hours following the call.
Codexis (Nasdaq: CDXS) announces a partnership with Molecular Assemblies to enhance enzymatic DNA synthesis. Codexis will invest $1 million in Series A preferred stock and gain an expected ownership stake over 10% through performance milestones. This collaboration leverages Codexis' CodeEvolver® technology to improve DNA polymerase enzymes, facilitating cost-effective, high-quality DNA production across industries like pharmaceuticals and synthetic biology. Both companies aim to revolutionize DNA synthesis and enable innovations in biotherapeutics, diagnostics, and data storage solutions.
Codexis, Inc. (Nasdaq: CDXS) welcomed two new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D., during its 2020 Annual Meeting of Stockholders. This addition aims to enhance the company’s focus on biotherapeutics development. Dr. Moore brings extensive experience from Allogene Therapeutics and Amgen, while Dr. Dilly has a robust background in executive management at Sierra Oncology and Aimmune Therapeutics. Additionally, Dr. Patrick Yang was re-elected to the board. These changes align with Codexis's strategy to strengthen its leadership in the biotechnology sector.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
What does Codexis, Inc. specialize in?
How does Codexis generate revenue?
What industries benefit from Codexis’ products and services?
What is the CodeEvolver® technology platform?
Where does Codexis derive its revenue from geographically?
What recent collaborations has Codexis entered into?
What is the significance of Codexis’ strategic collaborations?
What recent achievements has Codexis made in biotherapeutics?
How does Codexis ensure the quality of its products?
How can I stay updated with Codexis’ latest news and developments?
